title: Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition.
authors.forename: Andreas L
authors.initials: AL
authors.lastname: Birkenfeld
authors.forename: Frauke
authors.initials: F
authors.lastname: Adams
authors.forename: Christoph
authors.initials: C
authors.lastname: Schroeder
authors.forename: Stefan
authors.initials: S
authors.lastname: Engeli
authors.forename: Jens
authors.initials: J
authors.lastname: Jordan
mesh_terms: D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000613:Aminobutyrates / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001713:Biphenyl Compounds; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006333:Heart Failure / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011945:Receptors, Angiotensin / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology; D000068756:Valsartan; D018487:Ventricular Dysfunction, Left / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000318:Adrenergic beta-Agonists; D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000068756:Valsartan; D009320:Atrial Natriuretic Factor; D015260:Neprilysin; D007545:Isoproterenol; C549068:sacubitril and valsartan sodium hydrate drug combination